Overcoming Barriers to Low HPV Vaccine Uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9,2015

Jemal A Simard EP Dorell C Noone AM Markowitz LE Kohler B , Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175–201.

Stokley S Jeyarajah J Yankey D Cano M Gee J Roark J , Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR Morb Mortal Wkly Rep 2014;63(29):620–4.

Satterwhite CL Torrone E Meites E Dunne EF Mahajan R Ocfemia MC , Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187–93.

Gillison ML Chaturvedi AK Lowy DR . HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008;113(10 Suppl):3036–46.

National Cancer Institute (US). Accelerating HPV vaccine uptake: Urgency for action to prevent cancer. A report to the President of the United States from the President's Cancer Panel. Bethesda (MD): National Cancer Institute; 2014.

Holman DM Benard V Roland KB Watson M Liddon N Stokley S. Barriers to human papillomavirus vaccination among US adolescents: A systematic review of the literature. JAMA Pediatr 2014;168:76–82.

Vadaparampil ST Malo TL Kahn JA Salmon DA Lee JH Quinn GP , Physicians' human papillomavirus vaccine recommendations, 2009 and 2011. Am J Prev Med 2014;46:80–4.

Kahn JA Cooper HP Vadaparampil ST Pence BC Weinberg AD LoCoco SJ , Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11- to-12-year-old girls: A statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev 2009;18:2325–32.

National Vaccine Advisory Committee. The promise and challenge of adolescent immunization. Am J Prev Med 2008;35:152–7.

American Academy of Pediatrics. The medical home. Pediatrics 2002;110(1 Pt 1):184–6.

American Academy of Family Physicians. Immunizations [cited 2015 Dec 3]. Available from: http://www.aafp.org/about/policies/all/immunizations.html.

American Academy of Family Physicians. Letter to Suzanne Johnson-DeLeon, Health Education and Information Specialist, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. 2015 Mar 4 [cited 2015 Dec 3]. Available from: http://www.aafp.org/dam/AAFP/documents/advocacy/prevention/vaccines/LT-CDC-PediatricImmunization-030415.pdf.

Szilagyi PG Rand CM McLaurin J Tan L Britto M Francis A , Delivering adolescent vaccinations in the medical home: A new era? Pediatrics 2008;121(Suppl 1):S15–24.

Patient Protection and Affordable Care Act, 42 U.S.C. § 18001 et seq. (2010).

Shah PD Gilkey MB Pepper JK Gottlieb SL Brewer NT . Promising alternative settings for HPV vaccination of US adolescents. 2014 [cited 2014 Nov 7]. Available from: http://informahealthcare.com.ezproxyhhs.nihlibrary.nih.gov/doi/full/10.1586/14760584.2013.871204.

Lindley MC Boyer-Chu L Fishbein DB Kolasa M Middleman AB Wilson T , The role of schools in strengthening delivery of new adolescent vaccinations. Pediatrics 2008;121(Suppl 1):S46–54.

Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med 2000;18(1 Suppl):92–6.

Dobson SRM McNeil S Dionne M Dawar M Ogilvie G Krajden M , Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA 2013;309:1793–802.

Kreimer AR Rodriguez AC Hildesheim A Herrero R Porras C Schiffman Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444–51.

Romanowski B Schwarz TF Ferguson LM Ferguson M Peters K Dionne M , Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 2014;10:1155–65.

Lazcano-Ponce E Stanley M Muñoz N Torres L Cruz-Valdez A Salmerón J , Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014;32:725–32.

Harper DM Franco EL Wheeler CM Moscicki AB Romanowski B Roteli-Martins CM , Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006;367:1247–55.

Villa LL Costa RLR Petta CA Andrade RP Paavonen J Iversen OE , High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459–66.